Relmada Therapeutics Reported Results for REL-1017 in the P-III Trial for the Treatment of Major Depressive Disorders
Shots:
- The P-III (Study 310) clinical trial evaluates the safety & efficacy of REL-1017 (QD) in patients (n=627) with Major Depressive Disorder for a duration of 1yr. 423 of the total patients were rolled over from PBO-controlled trials with REL-1017 & 204 were de novo patients
- In de novo patients the results showed an improvement in mean MADRS total score of 11.3,16.8, 19.9 & 22.5 points, CR rates of 26.6%, 51.0%, 60.7%, 63.4% & 77.2%, clinical remission by 12.1%, 30.1%, 44.0%, 47.8% & 54.4%, improvement in CGI-I scores & reduction in functional impairment associated with MDD all marked at Day 7, 3mos., 6mos. & 12mos.
- REL-1017 is an NCE & NMDAR channel blocker targeting hyperactive channels while maintaining physiological glutamatergic neurotransmission
Ref: PRNewswire | Image: Relmada
Related News:- Relmada In-Licenses Psilocybin Program from Arbormentis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
